| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7579321 | SERENITY PHARMS LLC | Pharmaceutical compositions including low dosages of desmopressin |
May, 2023
(4 months ago) | |
| US7405203 | SERENITY PHARMS LLC | Pharmaceutical compositions including low dosages of desmopressin |
May, 2023
(4 months ago) | |
| US7799761 | SERENITY PHARMS LLC | Pharmaceutical compositions including low dosages of desmopressin |
Sep, 2024
(11 months from now) | |
| US11419914 | SERENITY PHARMS LLC | Safe desmopressin administration |
Jun, 2030
(6 years from now) | |
| US9539302 | SERENITY PHARMS LLC | Safe desmopressin administration |
Jun, 2030
(6 years from now) | |
Noctiva is owned by Serenity Pharms Llc.
Noctiva contains Desmopressin Acetate.
Noctiva has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Noctiva are:
- US7579321
- US7405203
Noctiva was authorised for market use on 03 March, 2017.
Noctiva is available in spray, metered;nasal dosage forms.
Noctiva can be used as treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic effect by intranasally administering a plume of droplets comprising a dose of about 0.05-5 mcg desmopressin, a method of treating nocturia due to nocturnal polyuria in adults.
The generics of Noctiva are possible to be released after 15 June, 2030.
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 03 March, 2017
Treatment: A method of treating nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic e...
Dosage: SPRAY, METERED;NASAL
NOCTIVA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic